Araris Biotech AG announces research agreement to develop next-generation ADCs using Araris’ AraLinQ technology

CAR-T Digest - August 2020

29 Apr 2025: Araris Biotech AG announces research agreement to develop next-generation ADCs using Araris’ AraLinQ technology

Araris Biotech has signed a research agreement with Johnson & Johnson to develop next-generation antibody-drug conjugates (ADCs)
The collaboration will utilize Araris’ proprietary AraLinQ platform, known for its efficient, one-step enzymatic conjugation method
AraLinQ technology enables the creation of highly uniform, stable, and potent ADC candidates with scalable and cost-effective production
This agreement follows previous collaborations with Taiho Pharmaceutical and Chugai Pharmaceutical, reinforcing AraLinQ’s industry relevance
The partnership aims to accelerate ADC development timelines and expand the application of Araris’ platform in targeted cancer therapy